Top partnerships Synaffix has a proven track record of technology out-licensing totaling over 7.6 billion in deals with major pharma and biotech partners, indicating a high propensity for strategic collaborations and licensing opportunities.

Clinical platform The company offers a clinical‑stage antibody-drug conjugate platform with a pipeline enabling rapid generation of best‑in‑class ADCs from any antibody, presenting multiple licensing and co-development avenues for partners seeking accelerated oncology solutions.

Recent expansions Recent announcements show active collaboration and licensing activity with industry players such as Boehringer Ingelheim, Elevation Oncology, Illumina, and Sidewinder Therapeutics, signaling growing demand for Synaffix technology and potential co‑development deals.

Strategic leverage Acquisition by Lonza in 2023 enhances credibility, scale, and go‑to‑market reach, suggesting opportunities for joint commercialization, preferred licensing terms, and wider access to distribution channels.

Market expansion Beyond ADCs, Synaffix technology is being deployed in immune cell engagers and targeted gene therapy, opening cross‑vertical sales opportunities with partners pursuing multi‑dollar, high‑growth indications.